somapacitan + Norditropin®
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Growth Hormone Deficiency in Children
Conditions
Growth Hormone Deficiency in Children
Trial Timeline
Jul 22, 2021 → Dec 18, 2023
NCT ID
NCT04970654About somapacitan + Norditropin®
somapacitan + Norditropin® is a phase 3 stage product being developed by Novo Nordisk for Growth Hormone Deficiency in Children. The current trial status is completed. This product is registered under clinical trial identifier NCT04970654. Target conditions include Growth Hormone Deficiency in Children.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05330325 | Phase 3 | Active |
| NCT04970654 | Phase 3 | Completed |
| NCT03878446 | Phase 2 | Active |
| NCT03811535 | Phase 3 | Completed |
Competing Products
20 competing products in Growth Hormone Deficiency in Children